Medikinet

Methylphenidate Hydrochloride, the active ingredient in Medikinet, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder (ADHD) and narcolepsy in children and adults.

GNH USA supplies Medikinet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medikinet is a central nervous system stimulant indicated for the following conditions:

- Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness. - Cognitive impairment associated with ADHD: enhances executive function and academic performance.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: gastrointestinal discomfort. - Irritability: mood swings or increased agitation. - Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmia. - Psychosis: emergence of hallucinations or delusional thoughts. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Priapism: prolonged painful erection. - Seizures: convulsive episodes in susceptible individuals. - Mood disorders: emergence of severe depression or suicidal thoughts.

Before initiating therapy, consider the following precautions:

- Cardiovascular assessment: evaluate blood pressure and cardiac history. - Psychiatric monitoring: watch for new or worsening mental health symptoms. - Growth monitoring: regularly track height and weight in pediatric patients. - Abuse potential: assess risk of misuse or dependence. - Concomitant MAO inhibitors: avoid use within 14 days of each other. - Store at room temperature: keep in the original container, protect from moisture and heat.

Methylphenidate may interact with several drug classes. Review the following:

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Antihypertensive agents: possible reduction of blood‑pressure‑lowering effect. - Tricyclic antidepressants: increased cardiovascular side effects. - Anticonvulsants: may alter methylphenidate plasma levels.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors: may raise methylphenidate concentrations. - Alcohol: can enhance central nervous system stimulation. - Antipsychotics: may diminish therapeutic response.